GlassScriptPhysician profile
Ann O Riggs
NPI 1124099072
$1,654.92
in general payments reported to CMS, 2019-2025
23 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $158 · 2021: $389 · 2022: $364 · 2023: $192 · 2024: $175 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.11 | 2021-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $203.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $176.35 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $134.06 | 2021-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.61 | 2021-2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $108.17 | 2019-2022 | |
| Astellas Pharma US INC | $65.86 | 2019-2025 | Veozah |
| Novo Nordisk INC | $60.48 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $40.40 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.97 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $29.30 | 2021 | |
| Adlon Therapeutics L.P. | $25.90 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $20.42 | 2023 | Spravato |
| Mylan Pharmaceuticals INC. | $19.72 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $19.26 | 2021 | |
| Eisai INC. | $19.19 | 2021 | |
| Endo Pharmaceuticals INC. | $17.99 | 2019 | |
| Boston Scientific Corporation | $17.81 | 2025 | Intracept |
| Allergan, INC. | $15.89 | 2020 | |
| Shire North American Group INC | $14.37 | 2019 | |
| Antares Pharma, INC. | $12.10 | 2019 | |
| Merck Sharp & Dohme LLC | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Riggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.